ARF6 and cancer: A series of our studies demonstrated that ARF6 and one of its downstream effectors, namely, AMAP1 (also called DDEF1 and ASAP1), constitute the core signaling machinery that drives cancer malignancy and therapeutic resistance when ARF6 is activated.